How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Bacteriophages Therapy Service Market
- By Therapy Type: Personalized Phage Therapy, Phage Cocktail Therapy, Phage-Derived Enzyme Therapy, Prophylactic Phage Therapy
- By Target Infection: Chronic Wound Infections, Respiratory Tract Infections, Urinary Tract Infections, Gastrointestinal Infections, Sepsis and Bloodstream Infections
- By End User: Hospitals and Clinics, Specialized Phage Therapy Centers, Research and Academic Institutions, Home Healthcare Services
- By Delivery Method: Topical Application, Oral Administration, Intravenous Injection, Inhalation Therapy
- By Phage Source: Natural Isolated Phages, Genetically Engineered Phages, Phage Libraries and Banks
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Personalized Phage Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Bacteriophages Therapy Service Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 4
Target Infection 5
End User 4
Delivery Method 4
Phage Source 3
Companies profiled
AmpliPhi Biosciences Corporation (now part of Armata Pharmaceuticals)
Armata Pharmaceuticals Inc.
Intralytix Inc.
Pherecydes Pharma
Adaptive Phage Therapeutics Inc.
Biophage Pharma
Eligo Bioscience
Locus Biosciences
Enbiotix Inc.
ContraFect Corporation
Fixed Phage
PhagoMed Biopharma
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →AmpliPhi Biosciences Corporation (now part of Armata Pharmaceuticals)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Armata Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Intralytix Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pherecydes Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Adaptive Phage Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Biophage Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Eligo Bioscience
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Locus Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Enbiotix Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →ContraFect Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Fixed Phage
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →PhagoMed Biopharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Micreos
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →SBI Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Phage International
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,427M by 2033 · 8.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Personalized Phage Therapy56.8
- Phage Cocktail Therapy18.7
- Phage-Derived Enzyme Therapy10.9
- Prophylactic Phage Therapy13.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$424.7M → $840.7M · 8.9%
Europe$296.0M → $606.7M · 9.4%
Asia Pacific$270.3M → $463.7M · 7.0%
Latin America$167.3M → $308.5M · 8.0%
Middle East and Africa$128.7M → $258.1M · 9.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.202026
8.222027
8.232028
8.232029
8.262030
8.272031
8.272032
8.282033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- AmpliPhi Biosciences Corporation (now part of Armata Pharmaceuticals)25.1
- Armata Pharmaceuticals Inc.12.8
- Intralytix Inc.7.2
- Pherecydes Pharma13.1
- Adaptive Phage Therapeutics Inc.5.0
- Biophage Pharma8.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type13.0%
Target Infection15.8%
End User25.5%
Delivery Method28.3%
Phage Source17.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.9
- Europe24.5
- Asia Pacific18.7
- Latin America12.5
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| AmpliPhi Biosciences Corporation (now part of Armata Pharmaceuticals) | 87 | 95 | 78 | 94 | 89 | 73 | 86 |
| Armata Pharmaceuticals Inc. | 74 | 82 | 93 | 79 | 87 | 70 | 81 |
| Intralytix Inc. | 69 | 81 | 63 | 75 | 78 | 69 | 73 |
| Pherecydes Pharma | 58 | 59 | 75 | 61 | 71 | 62 | 64 |
| Adaptive Phage Therapeutics Inc. | 65 | 64 | 71 | 61 | 67 | 59 | 65 |
| Biophage Pharma | 66 | 48 | 67 | 67 | 49 | 56 | 59 |
| Eligo Bioscience | 61 | 42 | 47 | 65 | 45 | 47 | 51 |
| Locus Biosciences | 49 | 59 | 45 | 36 | 53 | 37 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- AmpliPhi Biosciences Corporation (now part of Armata Pharmaceuticals)
- Armata Pharmaceuticals Inc.
- Intralytix Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| AmpliPhi Biosciences Corporation (now part of Armata Pharmaceuticals) | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Armata Pharmaceuticals Inc. | ◐ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Intralytix Inc. | − | ✓ | ✓ | ◐ | ✓ | ✓ |
| Pherecydes Pharma | − | − | ◐ | ◐ | ✓ | ◐ |
| Adaptive Phage Therapeutics Inc. | ◐ | ◐ | − | ◐ | ◐ | − |
| Biophage Pharma | ◐ | − | ◐ | ◐ | ◐ | − |
| Eligo Bioscience | − | ◐ | − | ✓ | − | ◐ |
| Locus Biosciences | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1AmpliPhi Biosciences Corporation (now part of Armata Pharmaceuticals)86
2Armata Pharmaceuticals Inc.81
3Intralytix Inc.73
4Adaptive Phage Therapeutics Inc.65
5Pherecydes Pharma64
6Biophage Pharma59
7Eligo Bioscience51
8Locus Biosciences47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
AmpliPhi Biosciences Corporation (now part of Armata Pharmaceuticals)Armata Pharmaceuticals Inc.
Challenger1
Strong scale, closing on the leaders.
Intralytix Inc.
Contender3
Focused players with pockets of strength.
Pherecydes PharmaAdaptive Phage Therapeutics Inc.Biophage Pharma
Niche2
Specialists in a single segment or region.
Eligo BioscienceLocus Biosciences
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Bacteriophages Therapy Service Market — a $591M beachhead inside a $8.59B market.
Beachhead (SOM)$591Mobtainable near-term
Serviceable (SAM)$3.26Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Personalized Phage Therapy
Best fit — highest urgency & budget in Therapy Type.
Economic buyer79 fit
Phage Cocktail Therapy
Strong fit — clear ROI and a fast path to value.
End user66 fit
Phage-Derived Enzyme Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Infection & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Bacteriophages Therapy Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified21%
Evaluation11%
Closed-won7%
$9.9KCAC
$52KLTV
5.3:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Bacteriophages Therapy Service Market is a resilient opportunity — $6.63B by 2033, compounding at 5.5%.
TAM · 2025$4.31Btoday
TAM · 2033$6.63Bforecast
CAGR5.5%2027–2033
Cumulative$48.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.63BTotal addressable market
SAM$2.35BServiceable available market
SOM$424MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.5% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.63BLarge & growingTAM by 2033 at 5.5% CAGR
$2.35BServiceable nowreachable with today’s model
$424MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.17BBear3.6% CAGR
$6.63BBase5.5% CAGR
$8.49BBull7.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Infection optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Bacteriophages Therapy Service Market — a $8.04B market by 2033. Plan: grow share from 10.0% to 16.7%.
Market size · 2033$8.04Btotal addressable
Market CAGR4.8%2027–2033
Target share16.7%from 10.0% today
Revenue ambition$1.34Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.0% | 16.7% | Ahead |
| Revenue | $879M | $1.34B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 36.2% | 42.4% | Behind |
| Customer retention | 89.8% | 95.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Target Infection capability
A defensible second engine — invest in Target Infection to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Infection
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $160M capacity & capability investment
- Greenlight bolt-on M&A in Target Infection
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Bacteriophages Therapy Service Market conversation — a $7.89B market you can size, segment and defend in minutes.
Market size · 2033$7.89Btotal opportunity
Growth5.3%CAGR to 2033
Addressable buyers1,499+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 2 mopayback period
$85K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
AmpliPhi Biosciences Corporation (now part of Armata Pharmaceuticals)Armata Pharmaceuticals Inc.Intralytix Inc.Pherecydes PharmaAdaptive Phage Therapeutics Inc.Biophage PharmaEligo BioscienceLocus Biosciences+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Bacteriophages Therapy Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Bacteriophages Therapy Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Anti-Counterfeiting Technologies Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportAir Ambulance Services Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportAI In Medical Imaging Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportAI for Pharma and Biotech Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportAutomated Dissolution Systems Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportAntibody Production Services Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportAmbulatory Surgical Centers (ASCs) Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportAmbulatory Services Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View report-86℃ Ultra-low Temperature Freezers Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportAmbulance Services Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View report7-Dehydrocholesterol Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View report7-Aminocephalosporanic Acid (7-ACA) Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.